BioMarin Pharmaceutical (HAM:BM8) Short Interest


HAM:BM8 BioMarin Pharmaceutical Inc HAM:BM8
79 GF Score
Price €48.79
GF Value €72.11
! 3 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

HAM:BM8 vs ARWR, MDGL, CYTK: Short Interest Comparison

For the Biotechnology subindustry, BioMarin Pharmaceutical's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioMarin Pharmaceutical Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's Short Interest distribution charts can be found below:

* The bar in red indicates where BioMarin Pharmaceutical's Short Interest falls into.


HAM:BM8
79GF Score
BioMarin Pharmaceutical Inc HAM:BM8
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioMarin Pharmaceutical (HAM:BM8) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of €48.79 is trading 32.3% below its estimated GF Value™ of €72.11.

Key valuation signals for HAM:BM8:

  • Short Interest:
  • GF Value™: €72.11 vs. price of €48.79 (32.3% below fair value)
  • GF Score™: 79/100 with 3 warning signs

No single metric tells the full story. See the HAM:BM8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
79GF Score

Get the complete analysis for HAM:BM8

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€48.79
Price
€72.11
GF Value